The extracellular matrix glycoprotein elastin microfibril interface located protein 2: A dual role in the tumor microenvironment

Neoplasia

Volumn 12, Issue 4, 2010, Pages 294-304

  Mongiat, Maurizio ^a   Marastoni, Stefano ^a   Ligresti, Giovanni ^a   Lorenzon, Erica ^a,d   Schiappacassi, Monica ^a   Perris, Roberto ^a,b   Frustaci, Sergio ^a   Colombatti, Alfonso ^a,c  

^a CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

^b UNIVERSITY OF PARMA   (Italy)

^c UNIVERSITY OF UDINE   (Italy)

^d UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; ELASTIN MICROFIBRIL INTERFACE LOCATED PROTEIN 2; GLYCOPROTEIN; UNCLASSIFIED DRUG;

ADULT; AMINO ACID SEQUENCE; AMINO TERMINAL SEQUENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL VIABILITY; COLON CANCER; CONTROLLED STUDY; EXTRACELLULAR MATRIX; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; TUMOR MICROENVIRONMENT; TUMOR VASCULARIZATION;

EID: 77951699330     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.91930     Document Type: Article

References (47)

1. Kalluri R and Zeisberg M (2006). Fibroblasts in cancer. Nat Rev Cancer 6, 392-401.
2. Sund M and Kalluri R (2009). Tumor stroma derived biomarkers in cancer. Cancer Metastasis Rev 28, 177-183.
3. Geiger TR and Peeper DS (2009). Metastasis mechanisms. Biochim Biophys Acta 1796,293-308.
4. Folkman J (1971). Tumor angiogenesis: therapeutic implications. N Engl J Med 285,1182-1186.
5. Thompson Coon JS, Liu Z, Hoyle M, Rogers G, Green C, Moxham T, Welch K, and Stein K (2009). Sunitinib and bevacizumab for first-line treatment of meta-static renal cell carcinoma: a systematic review and indirect comparison of clinical effectiveness. Br J Cancer 101, 238-243.
6. Sharieff W (2004).Bevacizumabincolorectalcancer. N Engl J Med 351, 1690-1691.
7. Sirohi B and Smith K (2008). Bevacizumab in the treatment of breast cancer. Expert Rev Anticancer Ther 8, 1559-1568.
8. Tol J, Koopman M, Cats A, Rodenburg CJ, Creemers GJ, Schrama JG, Erdkamp FL, Vos AH, van Groeningen CJ, Sinnige HA, et al. (2009). Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. N Engl J Med 360, 563-572.
9. Tao X, Sood AK, Deavers MT, Schmeler KM, Nick AM, Coleman RL, Milojevic L, Gershenson DM, and Brown J (2009). Anti-angiogenesis therapy with bevacizumab for patients with ovarian granulosa cell tumors. Gynecol Oncol 114, 431-436.
10. Hanahan D and Weinberg RA (2000). The hallmarks of cancer. Cell 100, 57-70.
11. Fulda S (2009). Tumor resistance to apoptosis. Int J Cancer 124, 511-515.
12. Hengartner MO (2000). The biochemistry of apoptosis. Nature 407, 770-776.
13. Pan G, O'Rourke K, Chinnaiyan AM, Gentz R, Ebner R, Ni J, and Dixit VM (1997). The receptor for the cytotoxic ligand TRAIL. Science 276, 111-113.
14. Walczak H, GliEsposti MA, Johnson RS, Smolak PJ, Waugh JY, Boiani N, Timour MS, Gerhart MJ, Schooley KA, Smith CA, et al. (1997). TRAIL-R2: a novel apoptosis-mediating receptor for TRAIL. EMBO J 16, 5386-5397.
15. LeBlanc HN and Ashkenazi A (2003). Apo2L/TRAIL and its death and decoy receptors. Cell Death Differ 10, 66-75.
16. Wu CH, Kao CH, and Safa AR (2008). TRAIL recombinant adenovirus triggers robust apoptosis in multidrug-resistant HL-60/Vinc cells preferentially through death receptor DR5. Hum Gene Ther 19, 731-743.
17. Ashkenazi A (2008). Targeting the extrinsic apoptosis pathway in cancer. Cytokine Growth Factor Rev 19, 325-331.
18. Johnstone RW, Frew AJ, and Smyth MJ (2008). The TRAIL apoptotic pathway in cancer onset, progression and therapy. Nat Rev Cancer 8, 782-798.
19. Sprick MR, Weigand MA, Rieser E, Rauch CT, Juo P, Blenis J, Krammer PH, and Walczak H (2000). FADD/MORT1 and caspase-8 are recruited to TRAIL receptors 1 and 2 and are essential for apoptosis mediated by TRAIL receptor 2. Immunity 12, 599-609.
20. Wang J, Chun HJ, Wong W, Spencer DM, and Lenardo MJ (2001). Caspase-10 is an initiator caspase in death receptor signaling. Proc Natl Acad Sci USA 98, 13884-13888.
21. Marastoni S, Ligresti G, Lorenzon E, Colombatti A, and Mongiat M (2008). Extracellular matrix: a matter of life and death. Connect Tissue Res 49, 203-206.
22. Chen Y and Du XY (2007). Functional properties and intracellular signaling of CCN1/Cyr61. J Cell Biochem 100, 1337-1345.
23. Juric V, Chen CC, and Lau LF (2009). Fas-mediated apoptosis is regulated by the extracellular matrix protein CCN1 (CYR61) in vitro and in vivo. Mol Cell Biol 29, 3266-3279.
24. Jimenez B, Volpert OV, Crawford SE, Febbraio M, Silverstein RL, and Bouck N (2000). Signals leading to apoptosis-dependent inhibition of neovascularization by thrombospondin-1. Nat Med 6, 41-48.
25. Shichiri M and Hirata Y (2001). Antiangiogenesis signals by endostatin. FASEB J 15,1044-1053.
26. Ramakrishnan S, Nguyen TM, Subramanian IV, and Kelekar A (2007). Autophagy and angiogenesis inhibition. Autophagy 3, 512-515.
27. Tai IT and Tang MJ (2008). SPARC in cancer biology: its role in cancer progression and potential for therapy. Drug Resist Updat 11, 231-246.
28. Tang MJ and Tai IT (2007). A novel interaction between procaspase 8 and SPARC enhances apoptosis and potentiates chemotherapy sensitivity in colorectal cancers. J Biol Chem 282, 34457-34467.
29. Seidler DG, Goldoni S, Agnew C, Cardi C, Thakur ML, Owens RT, McQuillan DJ, and Iozzo RV (2006). Decorin protein core inhibits in vivo cancer growth and metabolism by hindering epidermal growth factor receptor function and triggering apoptosis via caspase-3 activation. J Biol Chem 281, 26408-26418.
30. Doliana R, Bot S, Bonaldo P, and Colombatti A (2000). EMI, a novel cysteinerich domain of EMILINs and other extracellular proteins, interacts with the gC1q domains and participates in multimerization. FEBS Lett 484, 164-168.
31. Doliana R, Bot S, Mungiguerra G, Canton A, Cilli SP, and Colombatti A (2001). Isolation and characterization of EMILIN-2, a new component of the growing EMILINs family and a member of the EMI domain-containing superfamily. J Biol Chem 276, 12003-12011.
32. Mongiat M, Ligresti G, Marastoni S, Lorenzon E, Doliana R, and Colombatti A (2007). Regulation of the extrinsic apoptotic pathway by the extracellular matrix glycoprotein EMILIN2. Mol Cell Biol 27, 7176-7187.
33. Danussi C, Spessotto P, Petrucco A, Wassermann B, Sabatelli P, Montesi M, Doliana R, Bressan GM, and Colombatti A (2008). Emilin1 deficiency causes structural and functional defects of lymphatic vasculature. Mol Cell Biol 28, 4026-4039.
34. Wang S (2008). The promise of cancer therapeutics targeting the TNF-related apoptosis-inducingligandand TRAIL receptorpathway. Oncogene27, 6207-6215.
35. Ashkenazi A, Holland P, and Eckhardt SG (2008). Ligand-based targeting of apoptosis in cancer: the potential of recombinant human apoptosis ligand 2/tumor necrosis factor-related apoptosis-inducing ligand (rhApo2L/TRAIL). J Clin Oncol 26,3621-3630.
36. Duiker EW, Mom CH, de Jong S, Willemse PH, Gietema JA, van der Zee AG, and de Vries EG (2006). The clinical trail of TRAIL. Eur J Cancer 42, 2233-2240.
37. Braghetta P, Ferrari A, De GP, Zanetti M, Volpin D, Bonaldo P, and Bressan GM (2004). Overlapping, complementary and site-specific expression pattern of genes of the EMILIN/Multimerin family. Matrix Biol 22, 549-556.
38. Williams DA, Rios M, Stephens C, and Patel VP (1991). Fibronectin and VLA-4 in haematopoietic stem cell-microenvironment interactions. Nature 352, 438-441.
39. 1 Integrin-dependent cell adhesion to EMILIN-1 is mediated by the gC1q domain. J Biol Chem 278, 6160-6167.
40. Spessotto P, Bulla R, Danussi C, Radillo O, Cervi M, Monami G, Bossi F, Tedesco F, Doliana R, and Colombatti A (2006). EMILIN1 represents a major stromal element determining human trophoblast invasion of the uterine wall. J Cell Sci 119, 4574-4584.
41. Nakao S, Kuwano T, Ishibashi T, Kuwano M, and Ono M (2003). Synergistic effect of TNF-alpha in soluble VCAM-1-induced angiogenesis through alpha 4 integrins. J Immunol 170, 5704-5711.
42. 1 integrin. J Biol Chem 283, 18947-18956.
43. Gerber HP and Ferrara N (2005). Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in pre-clinical studies. Cancer Res 65, 671-680.
44. Ferrara N, Hillan KJ, Gerber HP, and Novotny W (2004). Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov 3, 391-400.
45. Epstein RJ (2007). VEGF signaling inhibitors: more pro-apoptotic than anti-angiogenic. Cancer Metastasis Rev 26, 443-452.
46. Jain RK (2005). Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 307, 58-62.
47. Kerbel RS (2006). Antiangiogenic therapy: a universal chemosensitization strategy for cancer? Science 312, 1171-1175.